Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2026 07:00 ET | Source: Profound Medical Corp.

Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative...
February 04, 2026 01:30 ET | Source: Curium

Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan

A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE)...
December 23, 2025 02:00 ET | Source: Curium

Curium Announces First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland

PYLCLARI® provides solutions to a wider patient group across Poland where there is high demand and unmet need PARIS, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine,...
November 19, 2025 07:40 ET | Source: Curium

Curium Announces First Commercial Doses of Diagnostic Radiopharmaceutical in Czech Republic and Slovakia for Patients with Prostate Cancer

Curium has entered a partnership with the Czech company ÚJV Řež, a leading expert in the development and production of radiopharmaceuticals, to manufacture diagnostic radiopharmaceuticals for patients...
October 15, 2025 02:30 ET | Source: Curium

Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan

PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., a registrational Phase 2 clinical trial has been initiated in Japan...
October 12, 2025 18:05 ET | Source: AdvanCell

AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO 2025

AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO 2025 Results from the Phase 1b dose escalation of the...
November 13, 2024 10:57 ET | Source: Curium

Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer

ST. LOUIS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that its ECLIPSE trial met its primary endpoint. ECLIPSE is a pivotal Phase 3, multi-center,...
March 07, 2024 08:51 ET | Source: Curium

Curium Announces First Commercial Doses in Italy of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial doses of PYLCLARI® have been sold in Italy. PYLCLARI® (INN:...
March 07, 2024 08:51 ET | Source: Curium

CURIUM ANNUNCIA LE PRIME DOSI COMMERCIALI IN ITALIA DI PYLCLARI® - UN INNOVATIVO TRACCIANTE PET 18F-PSMA INDICATO NEI PAZIENTI CON TUMORE ALLA PROSTATA

Parigi, Francia, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, leader mondiale nella medicina nucleare, ha annunciato oggi la vendita delle prime dosi commerciali di PYLCLARI® in Italia. PYLCLARI®...
February 22, 2024 06:19 ET | Source: Curium

Curium Announces Submission of the Marketing Authorization Application for PYLCLARI®, an Innovative (18F)-PSMA PET Tracer Indicated in Adults With Prostate Cancer to Swissmedic

PARIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the marketing authorization application for PYLCLARI® (INN: Piflufolastat (18F) formerly...